Pharmaceuticals
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
GAITHERSBURG, Md., Jan. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketing...
2023-01-18 21:00
4304
Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
EAST RUTHERFORD, N.J., Jan. 18, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has completed its acquisition of Snap...
2023-01-18 19:00
3885
Docquity delivers 10% market share growth for Philippine-based pharmaceutical client in just one year
* Docquity's leading network of HCPs and proprietary Awareness to Advocacy (A2A) solution complemented the Client's Sales and Marketing team to increase conversions in a highly competitive pain product market * Client was able to grow prescriptions and revenue, with over 80% cost savings comp...
2023-01-18 10:00
5102
Boehringer Ingelheim Malaysia Honored As Top Employer For The Fifth Consecutive Year
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition...
2023-01-18 09:00
3497
Boehringer Ingelheim Vietnam Honored As Top Employer For The Fourth Consecutive Year
HO CHI MINH CITY, Vietnam, Jan. 18, 2023 /PRNewswire/ -- Boehringer Ingelheim Vietnam has been honored for the fourth year in succession for its outstanding employee benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition. Globally, Boehringer Ingelheim has ...
2023-01-18 09:00
4430
Telix Reports Fourth Quarter 2022 Financial Results
MELBOURNE, Australia, Jan. 18, 2023 /PRNewswire/ -- 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended31 December 2022 (Q4 2022). All figures are in AUD$ ...
2023-01-18 08:50
4004
Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer
SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that it will present t...
2023-01-18 08:00
3448
Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
Study findings suggest that EVER206 is well-tolerated with no new safety signals, supporting next-phase clinical development inChina SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused on the development, manufacturing and comm...
2023-01-18 07:30
4795
Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD
SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor, pimicotinib (ABSK021), has been approved by the National Medical Products Administration ("NMPA") of the People's Republic ofChina for a phase II c...
2023-01-18 07:00
4590
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC
* World's first anti-PD-1 mAb for the first-line treatment of SCLC * Making a new record with the median OS of 15.8 months in an international, multi-center, phase 3 clinical trial * Granted orphan drug designations by the FDA and the EC, paving the way for international commercialization SH...
2023-01-17 19:42
4364
Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere
HANGZHOU and SHAOXING, China, Jan. 17, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a su...
2023-01-17 08:29
4099
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
Affamed to obtain sole commercialization rights upon regulatory approval in Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). Target to address unmet medical needs for millions of Chinese migraine patients. SHANGHAI, Jan. 17, ...
2023-01-17 08:00
6160
JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA
SINGAPORE, Jan. 12, 2023 /PRNewswire/ -- Singapore-headquartered Juniper
Biologics Pte Ltd
2023-01-12 13:02
3384
DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
- Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel 3-month ext...
2023-01-12 06:00
3378
CGTN: TCM continues to play significant role in treating COVID-19
BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role inChina's fight against COVID-19. As China is shifting the focus of its COVID-19 response from preventing infections to protecting people's health and preventing severe cases, the unique...
2023-01-11 23:09
4909
Bio4t2 announces first patient infused with CAR-T targeting solid tumors
SAN DIEGO, Jan. 11, 2023 /PRNewswire/ -- Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor (CAR) that targets overexpression of BT-001 antigen present on various types of solid tumors. The CAR-T (B4t2-001) was developed from Bio4t2's PrismCore™ platform. "This first...
2023-01-11 09:00
3579
MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval
GENEVA, Jan. 11, 2023 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel
sirolimus-eluting balloon, has received conditional FDA Investigational Device
Exemption (IDE) approval to initiate its pivotal clinical trial for the
treatment of coronaryde novo lesions.
2023-01-11 09:00
4280
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-01-11 00:00
4582
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
TOKYO, Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' ant...
2023-01-10 21:05
3500
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
* Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market * FDA market authorization advances personalized cancer care in Asia * Clearance sets the stage for continued R&D investment into early d...
2023-01-10 21:05
3981
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Nuix Neo Generative AI Framework
[Picked up by 260 media titles]
2026-10-08 08:02Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
12385
LEIFRAS Co., Ltd. Reports First Half of Fiscal Year 2026 Financial Results
2026-10-08 09:50
10024
XPENG G9L Completes First Production Trial in Europe
2026-10-08 07:33
9661
